R&D News | pharmaphorum

News

Evelo hit by SINTAX error in atopic dermatitis trial

Evelo Biosciences' lead drug candidate has failed a midstage trial in atopic dermatitis, wreaking havoc with its share price, but the biotech says it still plans to go ahe

News

Ratio raises $20m to build on its radiopharma ambitions

Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinica

News

Novartis drops Huntington's drug on phase 2b data

Tucked away inside Novartis' fourth-quarter results update this morning is the news that the company has pulled the plug on a drug candidate for Huntington's disease after

News

AstraZeneca partners Capitainer on biomarker project

Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.

News

Trial sets up earlier use of J&J's Carvykti in myeloma

One of Johnson & Johnson's top clinical trial readouts for 2023 just generated results, which bode very well for the future prospects of multiple myeloma CAR-T Carvykti.

News

UK biotech sees worst funding downturn since 2012

The UK BioIndustry Association (BIA) and data and insights company Clarivate have released their annual UK Biotech Financing report

Evelo hit by SINTAX error in atopic dermatitis trial

Ratio raises $20m to build on its radiopharma ambitions

Novartis drops Huntington's drug on phase 2b data

AstraZeneca partners Capitainer on biomarker project

Trial sets up earlier use of J&J's Carvykti in myeloma

UK biotech sees worst funding downturn since 2012

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks